Comparative

OMIA group 2819

Muscle weakness, CACNA1S-related

The chain

From the animal disease to the drugs. The page shows what each step found and where the chain stopped. It does not say whether the animal is a model of a human disease.

  1. Animal disease

    Reached

    OMIA records it in 1 species entry marked as a defect.

  2. Human disease

    Reached

    1 Mondo disease.

  3. Human gene

    Reached

    1 human gene.

  4. Target evidence

    Reached

    1 Open Targets association, with a best score of 0.77.

  5. Drugs

    Reached

    33 ChEMBL drugs, 29 approved. None has been tested for this disease.

Natural-model score

How complete and how well supported the chain to each human disease is, out of 100, by stated rules. It does not say that the animal is a validated model of the human disease. How the score works.

congenital myopathy 18

58.3 out of 100

Part Computed from Points
Target evidence Open Targets score of 0.77 26.8 of 35
Drugs Drugs act on its genes, but no drug has been tested for this disease 2.5 of 25
Ortholog One to one ortholog 20.0 of 20
Both routes One route found this disease 5.0 of 10
Species 1 naturally occurring species entry marked as a defect 4.0 of 10

Species

The chain follows only the species entries that OMIA marks as a defect.

Species Scientific name OMIA entry A defect
domestic cattle Bos taurus OMIA:002819-9913 Yes

Genes

Each gene OMIA records for a species entry, and the human gene it reaches through Ensembl's orthologs.

Species Animal gene Human gene Ortholog
domestic cattle CACNA1S calcium voltage-gated channel subunit alpha1 S NCBI Gene 100337204 CACNA1S Ensembl one to one

Human diseases

Two routes lead from an OMIA group to a Mondo human disease: OMIA's own Mondo link, and the group's OMIM numbers through Mondo's cross-references.

Mondo disease Name Found by
MONDO:0859514 congenital myopathy 18 OMIA's OMIM numbers

Target evidence

Each Open Targets association between one of the group's human genes and one of its human diseases, with its overall score and the score for each kind of evidence.

Human gene Human disease Score Evidence Kinds of evidence
CACNA1S congenital myopathy 18 0.77 652 Genetic association 0.92 Genetic literature 0.61 Animal model 0.52

Drugs

Drugs act on CACNA1S, but none has been tested for this disease.

Drug Acts on How Latest stage Tested for this disease
Amlodipine CACNA1S blocker Approved No
Azelnidipine CACNA1S blocker Approved No
Barnidipine CACNA1S blocker Approved No
Benidipine CACNA1S blocker Approved No
Bepridil CACNA1S blocker Approved No
Cilnidipine CACNA1S blocker Approved No
Cinnarizine CACNA1S blocker Approved No
Clevidipine CACNA1S blocker Approved No
Diltiazem CACNA1S blocker Approved No
Dronedarone CACNA1S blocker Approved No
Felodipine CACNA1S blocker Approved No
Gabapentin CACNA1S modulator Approved No
Gabapentin Enacarbil CACNA1S modulator Approved No
Isradipine CACNA1S blocker Approved No
Lacidipine CACNA1S blocker Approved No
Lercanidipine CACNA1S blocker Approved No
Levamlodipine CACNA1S blocker Approved No
Manidipine 6300 CACNA1S blocker Approved No
Nicardipine CACNA1S blocker Approved No
Nifedipine CACNA1S blocker Approved No
Nilvadipine CACNA1S blocker Approved No
Nimodipine CACNA1S blocker Approved No
Nisoldipine CACNA1S blocker Approved No
Nitrendipine CACNA1S blocker Approved No
Phloroglucinol CACNA1S blocker Approved No
Pregabalin CACNA1S modulator Approved No
Suloctidil CACNA1S blocker Approved No
Terodiline CACNA1S blocker Approved No
Verapamil CACNA1S blocker Approved No
Imagabalin CACNA1S modulator Phase 3 No
Atagabalin CACNA1S modulator Phase 2 No
Azd1305 CACNA1S blocker Phase 2 No
Elpetrigine CACNA1S blocker Phase 1 No

The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.